0001193125-20-112150.txt : 20200420 0001193125-20-112150.hdr.sgml : 20200420 20200420160556 ACCESSION NUMBER: 0001193125-20-112150 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200420 FILED AS OF DATE: 20200420 DATE AS OF CHANGE: 20200420 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics plc CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36866 FILM NUMBER: 20802607 BUSINESS ADDRESS: STREET 1: 136A EASTERN AVENUE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4SB BUSINESS PHONE: 44-123-544-3939 MAIL ADDRESS: STREET 1: 136A EASTERN AVENUE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4SB FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 6-K 1 d905387d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2020.

Commission File Number 001-36866

 

 

SUMMIT THERAPEUTICS PLC

(Translation of registrant’s name into English)

 

 

136a Eastern Avenue

Milton Park, Abingdon

Oxfordshire OX14 4SB

United Kingdom

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒                Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

On April 13, 2020, the Board of Directors (the “Board”) of Summit Therapeutics plc (the “Company) appointed current director Dr. Elaine Stracker as interim Chief Operating Officer of the Company.

On April 17, 2020, the Board (i) appointed current director Dr. Ventzislav Stefanov as Executive Vice President of the Company and President of Discuva and (ii) elected Ramses Erdtmann to serve as a non-executive director of the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    SUMMIT THERAPEUTICS PLC
Date: April 20, 2020     By:  

/s/ Robert Duggan

      Robert Duggan
      Chief Executive Officer